Childhood-onset lupus nephritis is characterized by complex interactions between kidney stroma and infiltrating immune cells
- PMID: 39602512
- PMCID: PMC11708815
- DOI: 10.1126/scitranslmed.adl1666
Childhood-onset lupus nephritis is characterized by complex interactions between kidney stroma and infiltrating immune cells
Abstract
Children with systemic lupus erythematosus (SLE) are at increased risk of developing kidney disease, termed childhood-onset lupus nephritis (cLN). Single-cell transcriptomics of dissociated kidney tissue has advanced our understanding of LN pathogenesis, but loss of spatial resolution prevents interrogation of in situ cellular interactions. Using a technical advance in spatial transcriptomics, we generated a spatially resolved, single-cell resolution atlas of kidney tissue from eight patients with cLN and four control individuals. Annotated cells were assigned to 30 reference cell types, including major kidney subsets and infiltrating immune cells. Analysis of spatial distribution demonstrated that individual immune lineages localized to specific regions in cLN kidneys, including myeloid cells that trafficked to inflamed glomeruli and B cells that clustered within tubulointerstitial immune hotspots. Gene expression varied as a function of tissue location, demonstrating how incorporation of spatial data can provide new insights into the immunopathogenesis of SLE. Alterations in immune phenotypes were accompanied by parallel changes in gene expression by resident kidney stromal cells. However, there was little correlation between histologic scoring of cLN disease activity and glomerular cell transcriptional signatures at the level of individual glomeruli. Last, we identified modules of spatially correlated gene expression with predicted roles in induction of inflammation and the development of tubulointerstitial fibrosis. Single-cell spatial transcriptomics allowed insights into the molecular heterogeneity of cLN, paving the way toward more targeted and personalized treatment approaches.
Conflict of interest statement
Competing interests:
The authors declare the following competing interests. P.D. is an employee at Bruker Corporation and has filed a patent covering the algorithm for spatial correlation analyses described in this manuscript (application number PCT/US2024/043413). N.H. no disclosures. E.D.N: no disclosures. J.E.R: no disclosures. N.R.: no disclosures. C.R.: no disclosures. E.W.Y.H.: no disclosures. K.H. received an unrestricted educational grant from Pfizer Global medical grants to support a quality improvement program for individuals with juvenile idiopathic arthritis (JIA) which was unrelated to the current study. D.M.O. is a consultant for a Horizon Therapeutics Advisory Board. C.E.A.: no disclosures. R.C.R: no disclosures. S.K.B. is an employee and shareholder at Sonoma Biotherapeutics and a shareholder of Sanofi. S.W.J. is a consultant for Merck, IgM BioSciences, and Sail BioMedicines and previously served as a consultant for Bristol-Myers Squib, Variant Bio, and ChemoCentryx, Inc. All other authors declare they have no competing interests.
Update of
-
Single cell spatial transcriptomic profiling of childhood-onset lupus nephritis reveals complex interactions between kidney stroma and infiltrating immune cells.bioRxiv [Preprint]. 2023 Nov 13:2023.11.09.566503. doi: 10.1101/2023.11.09.566503. bioRxiv. 2023. Update in: Sci Transl Med. 2024 Nov 27;16(775):eadl1666. doi: 10.1126/scitranslmed.adl1666. PMID: 38014158 Free PMC article. Updated. Preprint.
References
-
- Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA, Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med 383, 1117–1128 (2020); published online EpubSep 17 (10.1056/NEJMoa2001180). - DOI - PubMed
-
- Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB, Group A-LS, A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95, 219–231 (2019); published online EpubJan (10.1016/j.kint.2018.08.025). - DOI - PubMed
-
- Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB, Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070–2080 (2021); published online EpubMay 29 (10.1016/S0140-6736(21)00578-X). - DOI - PubMed
-
- Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall’Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B, S. L. E. n. Accelerating Medicines Partnership in, The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol 20, 902–914 (2019); published online EpubJul (10.1038/s41590-019-0398-x). - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
